Intensive glycemic compensation and prevention of chronic diabetic complications

Czech version

Authors: Vladimír Uličiansky
Authors‘ workplace: Via medica, s. r. o., Košice
Published in: Diab Obez 2019; 19(38): 121-126
Category: Clinical studies

Overview

Intensive glycemic compensation reduces risk of microvascular complications in type 1 and type 2 diabetics. Pharmacological treatment should be effective from the beginning, with the aimed dose titration and with gradual long-term reaching of individual target of HbA_1c. The ADVANCE study (therapy in intensive arm based on the original gliclazide MR) showed, that target levels of HbA_1c can be reached in effective and safe manner. Non-significant decrease of macrovascular complications in intensive arms of ADVANCE, ACCORD and VADT studies reflects multifactorial etiology of these complications. To prevent cardiovascular complications multifactorial approach is necessary, on the present gliclazide MR is preferred SU derivative by Slovak guidelines.

Keywords:

ACCORD study – ADVANCE study – DCCT study – gliclazide MR – intensive glycemic compensation – UKPDS study – VADT study

Sources

Schroner Z. Vzťah medzi intenzívnou antidiabetickou liečbou a prevenciou kardiovaskulárnych ochorení u diabetikov 2. typu. In: Schroner Z, Haluzík M, Mráz M et al. Antidiabetiká a kardiovaskulárne riziko. Typopress: Košice-Myslava 2017: 23–33 . ISBN 978–80–8129–073–2.
Nathan DM, Genuth S, Lachin J et al. [The Diabetes Control and Complications Trial Research Group]. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin–dependent diabetes mellitus. N Eng J Med 1993; 329(14): 977–986.
Nathan DM, Cleary PA, Backlund JY et al. [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group]. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 2005; 353(25): 2643–2653. Dostupné z DOI: <http://doi: 10.1056/NEJMoa052187>.
UK Prospective diabetes study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–853.
Holman RR, Paul SK, Bethel A et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Eng J Med 2008; 359(15): 1577–1589. Dostupné z DOI: <http://doi: 10.1056/NEJMoa0806470>.
Patel A, MacMahon S, Chalmers J et al. [ADVANCE Collaborative group]. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358(24): 2560–2572. Dostupné z DOI: <http://doi: 10.1056/NEJMoa0802987>.
Wong MG, Perkovic B, Chalmers J et al. [ADVANCE-ON Collaborative Group]. Long term benefits of intensive glucose control fo preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016; 39(5): 694–700. Dostupné z DOI: <http://doi: 10.2337/dc15–2322>.
Gerstein HC, Miller ME, Byington RP et al. [Action to Control Cardiovascular Risk in Diabetes Study Group]. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358: 2545–2559. Dostupné z DOI: <http://doi: 10.1056/NEJMoa0802743>.
[The ACCORD study group]. Nine-year effects of 3.7 years of intensive glucose control on cardiovascular outcomes. Diabetes Care 2016; 39(5): 701–708. Dostupné z DOI: <http://doi: 10.2337/dc15–2283>.
Duckworth W, Abraira C, Moritz T et al. [VADT Investigators]. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129–139. Dostupné z DOI: <http://doi: 10.1056/NEJMoa0808431>.
Hayward RA, Reaven PD, Wiitala WL et al. [VADT Investigators]. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372(23): 2197–2206. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1414266>.
Skyler JS, Bergenstal R, Bonow RO et al. [American Diabetes Association; American College of Cardiology Foundation; American Heart Association]. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE and VA Diabetes Trials. Diabetes Care 2009; 32(1): 187–192. Dostupné z DOI: <http://doi:10.2337/dc08–9026>.
Schroner Z, Uličiansky V. Význam metabolickej kompenzácie na vznik a progresiu chronických komplikácií pri diabetes mellitus 2. typu vo svetle najnovších klinických štúdií (ADVANCE, ACCORD, VADT). Interná med 2008; 8(7–8): 411–413.
Davies MJ, D Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2018 ; 61(12): 2461–2498. Dostupné z DOI: <http://doi: 10.1007/s00125–018–4729–5>.
Martinka M, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnost pre diabetes mellitus 2. typu (2018). Forum Diab 2018; 7(1): 47–68.
Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383–393. Dostupné z DOI: <http://doi: 10.1056/NEJMoa021778>.
Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. Engl J Med 2008; 358(6): 580–591. Dostupné z DOI: <http://doi: 10.1056/NEJMoa0706245>.
Gaede P, Oellgaard J, Carstensen B et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria.21 years follow-up of STENO-2 randomised trial. Diabetologia 2016; 59(11): 2298–2307. Dostupné z DOI: <http://doi: 10.1007/s00125–016–4065–6>.
Khunti K, Chatterjee S, Gerstein HC et al. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol. Lancet Diabetes Endocrinol 2018; 6(10): 821–832. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(18)30025–1>.
Uličiansky V. Deriváty sulfonylurey a kardiovaskulárne riziko. In: Schroner Z, Haluzík M, Mráz M et al. Antidiabetiká a kardiovaskulárne riziko. Typopress: Košice-Myslava 2017: 51–67. ISBN 978–80–8129–073–2.
Bergenstal RM, Bailey CJ, Kendall DM. Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications Am J Med 2010; 123(4): 374.e9–374.e18. Dostupné z DOI: <https://doiorg/10.1016/j.amjmed 2009.07.017>